Category: Press Releases

Genprex to Present at the 11th Annual LD Micro Main Event

AUSTIN, Texas & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Dec. 3, 2018-- Genprex, Inc. (NASDAQ: GNPX), a clinical-stage gene therapy company developing a new approach to treating cancer based upon a novel proprietary technology platform

Read More

Genprex Recognized as Finalist in Technology Innovation Category for Fierce Innovation Awards

AUSTIN, TX, November 29, 2017 – Genprex, Inc., a clinical stage gene therapy company, announced today that is has been selected as a finalist in this year’s Fierce Innovation Awards: Life Sciences Edition brought to you by the publisher of FierceBiotech and FiercePharma.

Read More

Genprex Provides Clinical and Corporate Update for Third Quarter 2018

AUSTIN, Texas--(BUSINESS WIRE)--Nov. 20, 2018-- Genprex, Inc. (NASDAQ:GNPX), a clinical stage gene therapy company developing a new approach to treating cancer based upon a novel proprietary technology platform, today announced a clinical and corporate update

Read More

Genprex Appoints Jan Stevens, RN, as Vice President of Clinical Operations

AUSTIN, Texas & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Oct. 30, 2018-- Genprex, Inc. (NASDAQ:GNPX), a clinical stage gene therapy company developing a new approach to treating cancer based upon a novel proprietary technology platform, announced today the appointment of Jan Stevens, RN

Read More

Genprex to Present at Upcoming Investor and Industry Conferences

AUSTIN,Texas & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Oct. 1, 2018-- Genprex, Inc. (NASDAQ: GNPX), a clinical stage gene therapy company developing a new approach to treating cancer based upon a novel proprietary technology platform

Read More

Genprex™ Taps Aldevron to Supply TUSC2 Plasmid DNA for Oncoprex Clinical Development Program

Newly manufactured plasmids will be applied in clinical trials evaluating Oncoprex™ in combination with targeted therapies and immunotherapies

Read More

Genprex CEO Updates Investors on Recent $10M Capital Raise and Progress of Oncoprex

AUSTIN, Texas & CAMBRIDGE, Mass.--Sept. 6, 2018-- Genprex, Inc. (NASDAQ: GNPX), a clinical stage gene therapy company developing a new approach to treating cancer based upon a novel proprietary technology platform

Read More

Genprex Amends Options to License Additional Cancer Fighting Technologies from the University of Texas MD Anderson Cancer Center

AUSTIN, Texas & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aug. 28, 2018-- Genprex, Inc. (NASDAQ: GNPX), a clinical stage gene therapy company developing a new approach to treating cancer based upon a novel proprietary technology platform, announced today
Read More

Genprex to Present at Upcoming Investor Conferences

AUSTIN, Texas & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aug. 21, 2018-- Genprex, Inc. (NASDAQ: GNPX), a clinical stage gene therapy company developing a new approach to treating cancer based upon a novel proprietary technology platform

Read More

Genprex Provides Clinical and Corporate Update for Second Quarter 2018

AUSTIN, Texas--(BUSINESS WIRE)--Aug. 15, 2018-- Genprex, Inc. (NASDAQ:GNPX), a clinical stage gene therapy company developing a new approach to treating cancer based upon a novel proprietary technology platform, today announced a clinical and corporate update

Read More

 
STAY IN THE KNOW WITH
EMAIL NEWS ALERTS
 
Don't miss out. Get our news delivered to your inbox.
 

 
close-link
 
Get Email News Alerts
 
close-link